《BioSpectrum Asia》Institute for the Biotechnology and Medicine Industry inks MoU with hospitals in APAC


Source: BioSpectrum Asia

At the Healthcare+ Expo, held at Nangang Exhibition Center in Taipei, Taiwan, from 1st to 4rth December 2022, the Institute for the Biotechnology and Medicine Industry (IBMI) signed Memorandums of Understanding (MoUs) with hospitals in the Asia Pacific (APAC) region.

The MoU signing ceremony involved the presence of Yang Pan-Chyr, VP IBMI; Tsai Chang-Hai, VP IBMI; Datuk Dr Kuljit Singh, President, Association of Private Hospital Malaysia; Dr Pongpat Patanavanich, Board of Mahachai Hospital chain; Dr Edmundo B. Lopez, President, Philippine Hospital Association; Dr Nguyen Van De, Chairman, Vietnam Private Hospital Association; Dr Iwan Dakota, President Director of National Cardiovascular Center Harapan Kita.

The main purpose of these MoUs is to jointly promote the bilateral cooperation and to contribute to improving the quality of medical services.

Before signing the MoU, Dr Nguyan Van de, Chairman of Vietnam Private Hospital Association said; “Vietnam is setting increasingly clear development visions, towards the goal of facilitating policies for private companies to take on more burden in the cause of public health, reduce the burden on the State Budget and put pressure on the public health system.” He further added, “Hopefully with advantage policy from Vietnam Government for investors, we will have much more convenience to expand investment cooperation and better development opportunities for each other.”

IBMI Vice President, Pan-Chyr Yang, said, “Following the global pandemic, the strategies were revised to respond to the post-COVID-19 economy. Those strategies revolved around sharpening Taiwan’s competitive edge by creating values and exploring novel applications through medical displays, medical AI and semiconductors in healthcare.”